Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

Launched by TIANJIN MEDICAL UNIVERSITY · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called PET/CT using a special substance called Pentixafor to help doctors see and diagnose diseases related to a protein known as CXCR4. This protein is often involved in certain types of tumors and other health conditions. The goal is to determine how effective this imaging method is in identifying both primary tumors and any that may have spread to other parts of the body.

The trial is currently looking for participants aged 18 to 75 who have suspected or confirmed untreated diseases related to CXCR4, such as certain blood cancers or other lymphoproliferative disorders. If you join the study, you will need to provide written consent and have a specific type of PET scan called 18F-FDG within two weeks before the new imaging test. However, individuals who are pregnant, breastfeeding, or have known allergies to Pentixafor cannot participate. This trial could provide valuable insights into better diagnosing and treating these conditions, so if you meet the criteria, you might want to consider participating!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
• • 18F-FDG PET/CT within two weeks
• • signed written consent.
• Exclusion Criteria:
• • pregnancy
• • breastfeeding
• • known allergy against Pentixafor